StoxRadar is free — only 218 spots left in beta.

SPY$773.93-0.42%QQQ$747.58-1.34%DIA$511.65+0.12%IWM$277.57-0.05%AAPL$340.42+1.11%MSFT$522.61-1.35%NVDA$230.48-2.94%AMZN$254.06-2.25%GOOGL$348.29-0.63%META$720.89-0.06%TSLA$375.00-0.74%JPM$331.42+0.56%GLD$378.62+0.73%BTC$36.12-2.06%IBIT$46.26-2.01%SPY$773.93-0.42%QQQ$747.58-1.34%DIA$511.65+0.12%IWM$277.57-0.05%AAPL$340.42+1.11%MSFT$522.61-1.35%NVDA$230.48-2.94%AMZN$254.06-2.25%GOOGL$348.29-0.63%META$720.89-0.06%TSLA$375.00-0.74%JPM$331.42+0.56%GLD$378.62+0.73%BTC$36.12-2.06%IBIT$46.26-2.01%

StoxRadar is free.

EVLO

EVLO

OTC

Evelo Biosciences, Inc.

Healthcare · Biotechnology

$0.00
+0.000.00%
Day Range: $0.00 – $0.00
Market Cap
$3,797
Volume
133
52W High
$0.00
52W Low
$0.00
P/E Ratio
-0.00
EPS (TTM)
$-26.28
Div Yield
—
Beta
1.40

Price History

08-2609-0309-1409-2209-30$0$0.000075$0.00015$0.000225$0.0003

Evelo Biosciences, Inc. is a biotechnology firm dedicated to identifying and advancing oral biologic therapies for various inflammatory conditions and oncological diseases. Its pipeline includes EDP1815, a whole-microbe compound designed to address inflammatory ailments, currently undergoing Phase 2 clinical trials for conditions such as psoriasis and atopic dermatitis, and also being evaluated for the hyperinflammatory reaction associated with COVID-19. Additional developments include EDP1867, an inactivated oral biologic in Phase 1b for inflammatory diseases; EDP2939, an investigational oral biologic based on extracellular vesicles targeting inflammatory diseases; and EDP1908, a drug candidate focused on cancer. Established in 2014, Evelo Biosciences, Inc. operates from its headquarters in Cambridge, Massachusetts.

CEO
Craig R. Jalbert
Employees
66
Headquarters
Cambridge, US
IPO Date
2018-05-08
BETA

Get started for full access.